Condition: Squamous Cell Carcinoma of Head and Neck · Sponsor: Janssen Research & Development, LLC
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refractory/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). HNSCC is a type of cancer that develops in the head and neck regions, including the outer tissue layer of the mouth and throat. This study will focus on participants with HNSCC who are treatment-naive (have not received prior treatment) in the R/M setting.
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| Ironwood Cancer and Research Center | Chandler, Arizona, United States | Recruiting |
| University of Arizona Cancer Center | Tucson, Arizona, United States | Recruiting |
| Providence St Jude Medical Center | Fullerton, California, United States | Recruiting |
| Scripps Health | La Jolla, California, United States | Recruiting |
| Valkyrie Clinical Trials | Los Angeles, California, United States | Recruiting |
| Valkyrie Clinical Trials Murrieta | Murrieta, California, United States | Recruiting |
| University Of California - Davis | Sacramento, California, United States | Recruiting |
| Stanford University Medical Center | Stanford, California, United States | Recruiting |
| Hartford Hospital | Hartford, Connecticut, United States | Recruiting |
| Yale Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Florida Cancer Specialists South | Fort Myers, Florida, United States | Recruiting |
| University of Miami Sylvester Comprehensive Cancer Center | Miami, Florida, United States | Recruiting |
+ 184 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07276399